Skip to main content
. 2015 Aug 3;33(26):2841–2847. doi: 10.1200/JCO.2015.61.4776

Fig 3.

Fig 3.

Overall survival with propensity score–matched sample for National Comprehensive Cancer Network patients with optimally cytoreduced, stage III ovarian cancer by first-line chemotherapy administration with intraperitoneal or intravenous (IP/IV) chemotherapy, 2006 to 2012.